Vestal Point Capital »

Beigene shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Beigene (BGNE) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Beigene

Tip: Access up to 7 years of quarterly data

All positions including Beigene held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Beigene by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $50M 350k 142.67

More positions owned by Vestal Point Capital

Jazz Pharmaceuticals Shs Usd (JAZZ)
Cytokinetics Com New (CYTK)
Ascendis Pharma A/S Sponsored Adr (ASND)
Ultragenyx Pharmaceutical (RARE)
Globus Medical Cl A (GMED)
Insmed Com Par $.01 (INSM)
BeiGene Sponsored Adr (BGNE)
Soleno Therapeutics (SLNO)
EXACT Sciences Corporation (EXAS)
Arcellx Common Stock (ACLX)
Immatics NV SHS (IMTX)
Janux Therapeutics (JANX)
Astria Therapeutics (ATXS)
Kalvista Pharmaceuticals (KALV)
Savara (SVRA)

View all positions for Vestal Point Capital

Top funds holding Beigene

Baker Bros. Advisors
Capital Research and Management Company - Division 3
Hillhouse Capital Advisors
PRIMECAP Management Company
Baillie Gifford & Co
Temasek Holdings
T. Rowe Price Associates
FMR
BlackRock
Capital International
Boxer Capital
Point72 Asset Management
Public Investment Fund
Vestal Point Capital
Artal Group

View all funds holding Beigene